Andreas Klosterman, Ph.D. (CEO) will give an update on selectION’s best-in-class ion channel antagonists and discuss the principles of the company’s systematical peptide design to obtain the most selective and specific ion channel blockers.
News & Events
- selectION, Inc. Initiates Dosing in Atopic Dermatitis Patients
- selectION, Inc. Advances Lead Program for Treatment of T Cell Mediated Autoimmune Diseases to Clinical Development
- Meet selectION, Inc. at the Biocom’s 2022 Global Life Science Partnering Conference in San Diego on February 22nd to 24th, 2022